Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,202 shares of the biopharmaceutical company’s stock after selling 1,514 shares during the quarter. UNIVEST FINANCIAL Corp’s holdings in Regeneron Pharmaceuticals were worth $10,116,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in REGN. State Street Corp grew its stake in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the last quarter. Amundi grew its position in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after acquiring an additional 22,538 shares during the period. TD Asset Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 8.9% in the 4th quarter. TD Asset Management Inc. now owns 359,389 shares of the biopharmaceutical company’s stock valued at $256,004,000 after acquiring an additional 29,322 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its position in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after purchasing an additional 1,108 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent research reports. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Citigroup lowered their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $634.14 on Wednesday. The company has a 50-day moving average of $687.18 and a two-hundred day moving average of $806.20. The stock has a market cap of $69.33 billion, a P/E ratio of 16.57, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12-month low of $633.10 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.86 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.